Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- MOMA Therapeutics
- Target Recruit Count
- 158
- Registration Number
- NCT06545942
- Locations
- 🇺🇸
Investigative Site #104, Lake Mary, Florida, United States
🇺🇸Investigative Site #110, Saint Louis, Missouri, United States
🇺🇸Investigative Site #103, New York, New York, United States
© Copyright 2024. All Rights Reserved by MedPath